|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The epsilon isoform of protein kinase C (PKCε) has recently been identified as a master switch that controls the nucleocytoplasmic trafficking of ATF2 and the survival of melanoma cells.
|
30497386 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that expression of a transcriptionally inactive form of Atf2 (Atf2(Δ8,9)) promotes development of melanoma in mouse models.
|
27210757 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we identify an IFNβ1-dependent, cell-autonomous mechanism that contributes to the therapeutic resistance of melanoma via the PKCɛ-ATF2 regulatory axis.
|
25728676 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, increased expression of the gene encoding PKCε and abundance of phosphorylated, transcriptionally active ATF2 were observed in advanced-stage melanomas and correlated with decreased FUK expression, decreased cellular protein fucosylation, attenuated cell adhesion, and increased cell motility.
|
26645581 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1.
|
26462148 |
2015 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the nucleus, ATF2 displays oncogenic activities in melanoma.
|
24968707 |
2014 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The imaging-based ATF2 translocation assay was conducted using UACC903 melanoma cells that stably express doxycycline-inducible GFP-ATF2.
|
23589174 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activating transcription factor 2 (ATF2; also known as cAMP-dependent transcription factor ATF-2) has oncogenic activities in melanoma and tumor suppressor activities in non-malignant skin tumors and breast cancer.
|
22685333 |
2012 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytoplasmic localization of ATF2 was observed in melanoma, brain tissue from patients with Alzheimer disease, prostate cancer specimens, and ionizing radiation-treated prostate cancer cells, suggesting that alteration of ATF2 subcellular localization may be involved in the pathogenesis of these diseases.
|
22275354 |
2012 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings establish the importance of transcriptionally active ATF2 in melanoma development through fine-tuning of MITF expression.
|
21203491 |
2010 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibiting ATF2 suffices to impede melanoma development.
|
18677098 |
2008 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations within the JNK binding region of ATF2(50-100) or expression of TAM67 or JunD RNAi attenuates inhibition of melanoma's tumorigenicity by ATF2(50-100).
|
15010535 |
2004 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Piperine is a potent inhibitor of nuclear factor-kappaB (NF-kappaB), c-Fos, CREB, ATF-2 and proinflammatory cytokine gene expression in B16F-10 melanoma cells.
|
15531295 |
2004 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
To determine the prognostic value of ATF2 in melanoma, we evaluated the pattern and level of ATF2 expression in a large cohort of melanoma specimens.
|
14678960 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changes at genomic, transcriptional and post-translational levels of G-proteins and protein kinases (Ras, B-Raf) and their transcription factor effectors (c-Jun, ATF2, Stat3 and NF-kappaB) affects TNF, Fas and TRAIL receptors, which play important roles in acquiring melanoma's resistance to apoptosis.
|
12789291 |
2003 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our findings suggest that ATF2 contributes to UVC-induced apoptosis through transcriptional silencing of TNFalpha, which balances Fas-mediated cell death in melanoma.
|
10318823 |
1999 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that ATF2 is a regulator of radiation and drug resistance in melanomas, and that tumor targeted ATF2 modulators may be useful sensitizers in the treatment of tumors of this type.
|
9484842 |
1998 |